";s:4:"text";s:5613:" The drug has been implicated in the production of myocardial infarction. (The following frequency estimates are used: frequent > 10 %, occasional 1-10%, rare 0.001-1%, isolated cases < 0.001%)Occasionally: flushing, hypotension, anginal symptoms.Isolated cases: peripheral neuritis, polyneuritis, paraesthesiae (these unwanted effects may be reversed by administering pyridoxine).Rarely: proteinuria, increased plasma creatinine, haematuria sometimes in association with glomerulonephritis.Isolated cases: acute renal failure, urinary retention.Occasionally: gastro-intestinal disturbances, diarrhoea, nausea, vomiting.Rarely: jaundice, liver enlargement, abnormal liver function sometimes in association with hepatitis.Rarely: anaemia, leucopenia, neutropenia, thrombocytopenia with or without purpura.Isolated cases: haemolytic anaemia, leucocytosis, lymphadenopathy, pancytopenia, splenomegaly, agranulocytosis.Rarely: increased lacrimation, conjunctivitis, nasal congestion.Occasionally: SLE-like syndrome (sometimes resulting in a fatal outcome see section 4.4 Special warnings and precautions for use).Rarely: hypersensitivity reactions such as pruritus, urticaria, vasculitis, eosinophilia, hepatitis.Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Where discontinuation of therapy in heart failure is indicated, Apresoline/Hydralazine Tablets should be withdrawn gradually (except in serious situations, such as SLE-like syndrome or blood dyscrasias) in order to avoid precipitation and/or exacerbation of heart failure.Patients with rare hereditary problems of fructose intolerance, glucosegalactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.Potentiation of effects: Concurrent therapy with other antihypertensives (vasodilators, calcium antagonists, ACE inhibitors, diuretics), anaesthetics, tricyclic antidepressants, major tranquillisers, nitrates or drugs exerting central depressant actions (including alcohol).Administration of Apresoline/Hydralazine Tablets shortly before or after diazoxide may give rise to marked hypotension.MAO inhibitors should be used with caution in patients receiving Apresoline/Hydralazine Tablets.Concurrent administration of Apresoline/Hydralazine Tablets with beta-blockers subject to a strong first pass effect (e.g. 0000046300 00000 n
0000007110 00000 n
This information is intended for use by health professionalsThe active ingredient is 1-hydrazinophthalazine hydrochloride (hydralazine hydrochloride). 0000046385 00000 n
If 100 mg daily fails to elicit an adequate clinical effect, the patient's acetylator status should be evaluated. Supportive measures including intravenous fluids are also indicated. Benign interstitial cell tumors of the testes were also significantly increased in male rats from the high-dose group. 0000005502 00000 n
Excipient(s) with known effects.
Call your doctor for medical advice about side effects. Date of first authorisation/renewal of the authorisationStart typing to retrieve search suggestions. 63739-327-10 0000049661 00000 n
0000044289 00000 n
To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader. Downward adjustment of these drugs may be required when they are given concomitantly with Apresoline/Hydralazine Tablets.There is potential for the hypotensive effect of hydralazine to be antagonised when used concomitantly with oestrogens or non-steroidal anti-inflammatory drugs.Use of Apresoline in pregnancy, before the third trimester should be avoided but the drug may be employed in later pregnancy if there is no safer alternative or when the disease itself carries serious risks for the mother or child e.g. It has been found to be particularly useful in heart failure, together with isosorbide dinitrate, for treatment of people of African descent. Its precise mode of action is not known.
5-10 mg IV/IM initially, THEN 5-10 mg q20-30min PRN, OR Tablets also contain anhydrous lactose, FD&C yellow no. h�b```e``�d`c`(�g�g@ ~�����&0�F�Op� ��%N�]x'�Ib���f��t{��`5iiH�$���,���s[�E����-����0��@ԉ�SAZ��u�P��C��D�bDf�T�mn�}Qm�m���0�x��o�a7�y����Z"��a�rB�h�A[���@k 25 mg, 50 mg or 100 mg tablets also contain Anhydrous Lactose, Microcrystalline Cellulose, Sodium Starch 0000055950 00000 n